A detailed history of Ninepoint Partners LP transactions in Argenx Se stock. As of the latest transaction made, Ninepoint Partners LP holds 200 shares of ARGX stock, worth $181,596. This represents 0.02% of its overall portfolio holdings.

Number of Shares
200
Holding current value
$181,596
% of portfolio
0.02%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025

BUY
$538.64 - $768.0 $107,728 - $153,600
200 New
200 $147,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $50.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Ninepoint Partners LP Portfolio

Follow Ninepoint Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ninepoint Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Ninepoint Partners LP with notifications on news.